We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Myriad Genetics Inc | NASDAQ:MYGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 2.57% | 19.97 | 18.68 | 22.07 | 20.20 | 19.47 | 19.57 | 640,224 | 23:00:06 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ | Filed by a Party other than the Registrant ☐ |
Check the appropriate box:
☐ |
Preliminary Proxy Statement 1 | |
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
☐ |
Definitive Proxy Statement | |
☒ |
Definitive Additional Materials | |
☐ |
Soliciting Material Under Rule 14a-12 |
Myriad Genetics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ |
No fee required. | |||
☐ |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
1) | Title of each class of securities to which transaction applies: | |||
|
||||
2) | Aggregate number of securities to which transaction applies: | |||
|
||||
3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |||
|
||||
4) | Proposed maximum aggregate value of transaction: | |||
|
||||
5) | Total fee paid: | |||
|
||||
☐ |
Fee paid previously with preliminary materials. | |||
☐ |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing: | |||
1) | Amount previously paid: | |||
|
||||
2) | Form, Schedule or Registration Statement No: | |||
|
||||
3) | Filing party: | |||
|
||||
4) | Date Filed: | |||
|
*** Exercise Your Right to Vote ***
Important Notice Regarding the Availability of Proxy Materials
MYRIAD GENETICS, INC.
MYRIAD GENETICS, INC. ATTN: CORPORATE SECRETARY 320 WAKARA WAY SALT LAKE CITY, UT 84108
|
Meeting Information
Meeting Type: Annual
For holders as of: October 4, 2017
Date: November 30, 2017 Time: 9:00 AM MST
Location: Offices of Myriad Genetics, Inc. 320 Wakara Way Salt Lake City, UT 84108
|
|||||||
You are receiving this communication because you hold shares in the company named above. |
||||||||
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).
We encourage you to access and review all of the important information contained in the proxy materials before voting.
|
||||||||
See the reverse side of this notice to obtain proxy materials and voting instructions.
|
||||||||
|
Voting Items |
The Board of Directors recommends that you vote FOR the following: |
||||||||||||
1. | Election of three Class III Directors (or if any nominee is not available for election, such substitute as the Board of Directors may designate) for a three-year term. | |||||||||||
Nominees: | ||||||||||||
01) Walter Gilbert Ph.D. |
||||||||||||
02) Dennis H. Langer M.D., J.D. |
||||||||||||
03) Lawrence C. Best |
||||||||||||
The Board of Directors recommends you vote FOR the following proposals: | ||||||||||||
2. | To approve the proposed 2017 Employee, Director and Consultant Equity Incentive Plan. | |||||||||||
3. | To re-approve our 2013 Executive Incentive Plan, as amended. | |||||||||||
4. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2018. | |||||||||||
5. | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. | |||||||||||
The Board of Directors recommends you vote 1 year on the following proposal: | ||||||||||||
6. | To approve, on an advisory basis, on the frequency of holding an advisory vote on the compensation of our named executive officers. | |||||||||||
In their discretion, the proxies are authorized to vote upon such other matters as may properly come before the meeting or any adjournments or postponements thereof. | ||||||||||||
|
|
||||
|
||||
|
1 Year Myriad Genetics Chart |
1 Month Myriad Genetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions